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Abstract
Abnormalities of intracellular Ca2+ homeostasis and signalling as well as the down-regula-
tion of neurotrophic factors in several areas of the central nervous system and in peripheral
tissues are hallmarks of Huntington’s disease (HD). As there is no therapy for this heredi-
tary, neurodegenerative fatal disease, further effort should be made to slow the progression
of neurodegeneration in patients through the definition of early therapeutic interventions.
For this purpose, molecular biomarker(s) for monitoring disease onset and/or progression
and response to treatment need to be identified. In the attempt to contribute to the research
of peripheral candidate biomarkers in HD, we adopted a multiplex real-time PCR approach
to analyse the mRNA level of targeted genes involved in the control of cellular calcium ho-
meostasis and in neuroprotection. For this purpose we recruited a total of 110 subjects pos-
sessing the HDmutation at different clinical stages of the disease and 54 sex- and age-
matched controls. This study provides evidence of reduced transcript levels of sarco-endo-
plasmic reticulum-associated ATP2A2 calcium pump (SERCA2) and vascular endothelial
growth factor (VEGF) in peripheral blood mononuclear cells (PBMCs) of manifest and pre-
manifest HD subjects. Our results provide a potentially new candidate molecular biomarker
for monitoring the progression of this disease and contribute to understanding some early
events that might have a role in triggering cellular dysfunctions in HD.
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Introduction
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder involving
brain and systemic alterations. The disease is characterized, among others, by the progressive
loss of striatal medium spiny neurons, with an onset of symptoms at a mean age of 45 years.
Progressive motor and cognitive decline and the development of psychiatric symptoms [1,2]
are well known signs of the disease. HD is caused by the expansion of a polyglutamine stretch
in the huntingtin (HTT) protein [3]. Mutant huntingtin (mHTT) gains toxic function [4–15],
primarily in medium spiny neurons (MSNs) [16], with aberrant interactions in several path-
ways, including gene expression, oxidative stress, mitochondrial function, energy metabolism,
Ca2+ homeostasis and signalling. mHTT is ubiquitously expressed and there is growing evi-
dence that the mutant protein causes cytotoxicity not only in the central nervous system but
also in the peripheral tissue of patients with HD [17]. Unfortunately, there is no known cure
for this disease. To plan an early and effective therapeutic intervention, it is necessary to know
the molecular mechanisms that trigger cellular dysfunction in HD, even in the period preced-
ing the onset of symptoms. Furthermore, molecular biomarker(s) for the monitoring of disease
onset and/or progression and response to treatment, need to be identified. However, the non-
invasive detection of clinically useful biomarkers is a challenge faced by many research labora-
tories in the last few years. Multiple alterations in gene expression patterns, mainly using mi-
croarray technology and the further validation of selected genes, have been shown in the
peripheral tissues of HD patients and in the peripheral blood of mouse models of HD [17–24].
For instance, variation in the expression level of genes involved in energy metabolism, oxida-
tive stress and inflammatory response in peripheral leukocytes of HD patients with respect to
control individuals have been reported [21–23]. Different studies have suggested that the toxic
mHTT gain of function may involve disturbed glutamate-induced Ca2+ signalling in MSNs
[9,25]. It has been reported that mHTT facilitates the activity of NMDA receptors [15,26–30]
and type 1 inositol 1,4,5-triphosphate receptors (InsP3R1) [31,32], leading to enhanced intra-
cellular Ca2+ concentrations in HD neurons. Furthermore, in peripheral tissues altered RNA
expression of genes linked to Ca2+ homeostasis in HD patients with respect to controls has
been reported (17). In spite of the fact that one of the hallmarks of HD is an impairment of the
intracellular Ca2+ concentration and signalling, only recently the expression of genes encoding
the calcium signalosome has been investigated in cellular and transgenic models of HD [33]. In
this paper the authors describe changes in the gene expression of members of the calcium sig-
nalosome. However, these changes differ in the two models of HD used in the study. To date,
the gene expression of calcium pumps dedicated to the extrusion of calcium from the cyto-
plasm (PMCA1-4 isoforms) or its storage in the cisterns of the endoplasmic reticulum (SERCA
pumps) has not yet been directly explored. In this work, we investigated the mRNA levels of
both the housekeeping-expressed plasma membrane-associated PMCA1 isoform [34–35] and
the sarco-endoplasmic reticulum-associated (SERCA2 and SERCA3) pumps in PBMCs from
manifest and pre-manifest HD patients compared to sex- and age-matched controls.
Furthermore, to date, the expression level of neurotrophic and neuroprotective agents as po-
tential tracer(s) of disease onset and/or progression has not been sufficiently explored. Indeed,
neurotrophic factors such as brain-derived neurotrophic factor, glial-derived neurotrophic fac-
tor and ciliary neurotrophic factor are transcriptionally deregulated in HD striatal neurons and
have been found to be neuroprotective in a variety of animal models of HD [18–20,36,37].
Among others, vascular endothelial growth factor (VEGF) has neurotrophic and neuroprotec-
tive properties in addition to its well-known angiogenic functions. VEGF directly exerts neuro-
protective actions, through the inhibition of programmed cell death or apoptosis and the
stimulation of neurogenesis [38–45], as well as indirectly, by activating antioxidants,
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promoting angiogenesis and enhancing blood brain barrier permeability for glucose [46–53].
Although VEGF acts as an endogenous neuroprotective factor, it is produced by both neuronal
and non-neuronal cells, including endothelia and astroglia. VEGF released from these sources
might target VEGF receptors on the surface of neurons [40] and contribute to their tropism
and survival.
In this study, we also investigated the level of VEGF mRNA expression in PBMCs from the
above-described cohort of HD and control subjects. Our results provide a potentially new mo-
lecular biomarker for monitoring the progression of the disease and shed new light on some
early events that may contribute to cellular dysfunction in HD.
Materials and Methods
Human ethics
All samples were obtained in accordance with the institutional Bioethics Committee named
“Comitato Etico dell’Azienda Ospedaliero-Universitaria Santa Maria della Misericordia”, which
approved this study. The patients or their legal guardians gave written informed consent.
Patients recruitment and samples collection
All the patients and controls were residents of Italy and Slovenia. The HD group consisted of
90 HD manifest patients, of which 45 were male and 45 female (average age 54.1 ± 12.8 years),
and 20 HD pre-manifest patients, 10 male and 10 female (average age 38.8 ± 8.4 years). The
control group consisted of 54 healthy subjects (33 male and 22 female) matched for sex and
age, who were recruited among blood donors and without a family history of HD. All samples
were collected between 9,00 and 10,00 a.m. in fasting conditions and a sample (5 ml) of periph-
eral blood was collected in Vacutainer tubes with EDTA and processed with FicollPaque (GE
Healthcare) according to the manufacturer’s instructions. Peripheral blood mononuclear cells
(PBMCs) were collected.
Clinical classification of patients
All the subjects, patients and controls, were grouped arbitrary in three range of age (27–40; 43–
58; 59–84 years old; range of CAG repeats 47–57, 49–56 and 37–49 respectively) in an attempt
to account for aging-dependent variation of gene expression. Alternatively, where indicated,
the HD patients enrolled in this study were stratified upon their neurological status. The Uni-
fied Huntington’s Disease Rating Scale (UHDRS) by an experienced HD neurologist has been
used to determine neurological status. All of the manifest patients were in stages I or II of HD
as determined by total functional capacity scores of 7–12. UHDRS total motor score
(UHDRS-TMS) between 5 and 24 defined early-manifest patients, UHDRS-TMS between 25
and 50 defined manifest patients, and a score of more than 50 defined late-manifest HD pa-
tients. In summary, the 20 pre-manifest patients (mean age 40.9 ± 5.5 years), relatives of al-
ready manifest subjects, were carriers of the HD-causing mutation (range of CAG repeats 39–
48) but still negative by clinical evaluation; the 17 early-manifest patients (mean age
47.9 ± 10.5; range of CAG repeats 40–52) experienced the onset of poor control of voluntary
movements of the limbs and facial grimaces with or without psychic disorders; the 18 late-
manifest patients (mean age 59.3 ± 11.9 years; range of CAG repeats 40–57) usually presented
dementia as well as marked hyperkinesis or even severe spastic tetraplegia and mutism. The re-
maining 55 subjects (mean age 52.2 ± 11.1 years; range of CAG repeats 37–50) were grouped
in the manifest category.
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No patients had any medication suspected or known to interfere with the experimental
methods used and/or with the gene expressions analysed.
DNA extraction and molecular diagnosis of HD
DNA was isolated using the Purgene DNA Purification kit (Gentra Systems) according to the
manufacturer’s instructions. The DNA concentration was determined using the Quantifluor
dsDNA System (Promega), and the DNA quality was determined on a 1% agarose gel (TBE 0.5
X) with GelRed (Biotium) using Lambda DNA/HindIII as a marker of molecular weight
(Fermentas).
To evaluate the number of CAG repeats and to exclude false homozygous states that can be
due to the occurrence of SNPs in the region of primer annealing, we performed three indepen-
dent PCR reactions. Briefly, the primers HD1F and HD3R were used to amplify the CAG re-
peat, HD4 and HD5 were used to amplify the CCG repeat immediately downstream of the
CAG region, and HD1 and HD5 were used to amplify the entire CAGCCG region. The se-
quences of the primers and references are shown in Table 1. The protocol of the PCR reaction
mix and cycles was optimized to be unique in getting separate amplicons of the three repeated
regions. Precisely, the PCR reactions were performed in a final volume of 25 μl containing 4 μl
of each specific primer (5 pmol/μl), 2.5 μl of buffer 10X (Applied Biosystem), 7.5 μl glycerol
50%, 0.88 μl dimethyl-formamide, 1.0 μl dNTPs (5 mM), 0.38 μl AmpliTaq DNA polymerase
(5 U/μl) (Applied Biosystems), 2 μl of genomic DNA (100 ng/μl) previously denaturated at
95°C for 7 min and water to 25 μl. The amplification was performed with an initial denatur-
ation at 94°C for 1 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at
66°C for 30 sec and elongation at 72°C for 30 sec and a final extension at 72°C for 7 min. The
PCR fragments were resolved by capillary electrophoresis on an automated ABI Prim 3730 XL
Genetic Analyzer in presence of HiDi formamide and Gene Scan 500-LIZ 500 internal size
standard (Applied Biosystems). The data were analysed using Peak Scanner Software (Life
Technologies).
RNA preparation and reverse transcription
Total RNA from PBMCs was extracted with RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s instructions, and 450 ng of total RNA was reverse-transcribed using SuperScript III
Reverse Transcriptase (Life Technologies) and random hexaprimers (Invitrogen), according to
the manufacturer’s instructions. Three independent reactions were performed for each RNA
sample to correct for inter-assay variability. Briefly, the RNA plus random hexaprimers was
rapidly denatured at 65°C for 5 min, and the RT-PCR protocol was carried out as follows: 55°C
for 60 min, 70°C for 15 min and 95°C for 5 min, followed by cooling at 4°C. The three RT-PCR
products, relative to each RNA sample, were pooled and used in three independent real-time
PCR assays.
Table 1. Primers used to evaluate the number of CAG repeats for the molecular diagnosis of HD.
Name Sequence Length Amplified Region Reference
HD1F ATGAAGGCCTTCGAGTCCCTAAAGTCCTTC 30 bp CAG [54]
HD3R GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC 30 bp
HD4F GCAGCAGCAGCAGCAACAGCCGCCACCGCC 30 bp CCG [55]
HD5R GCGGCGGCTGAGGAAGCTGAG 21 bp
doi:10.1371/journal.pone.0125259.t001
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Relative RNA quantification
For the detection and relative quantification of target gene transcripts, TAQMan gene expression
assays (Applied Biosystems) and a 7500 Real-Time PCR System (Applied Biosystems) were used.
β-actin was used as the reference gene. Each target and reference gene were co-amplified in the
same reaction tube to minimise variability. The list of human assays for target genes is shown in
Table 2. The sequences of the primers and probe used for β-actin are reported in Table 3. Probes
specific for the target genes were labelled with the FAM fluorophore, and the β-actin probe was
labelled with the VIC fluorophore. Each duplex real-time PCR contained 6.5 μl of 2XMasterMix
(Applied Biosystems), 0.3 μl of gene-specific TAQMan gene expression assay, 0.55 μl of β-actin
forward primer (10 μM), 0.55 μl of β-actin reverse primer (10 μM), 0.125 μl of β-actin probe
(10 μM), 0.5 μl 50 mMMgCl2, 2 μl cDNA template and water to 12.5 μl. In all the assays the
gene expression levels detected in the samples tested have been reported to the gene expression
levels detected in the ARO cell line that was used as an internal calibrator sample.
Data processing and statistical analysis
Experimental data from real-time PCR were reported as threshold cycle (Ct) values and summa-
rized as mean ± SD of three independent experiments, as indicated in the figure legends. Each ex-
periment was performed on individual samples in triplicate. Ct values for each gene were
normalized to internal control (β-actin) that was run with each tested sample. Differences in
gene expression were calculated using the ΔΔCt method, as previously described [56]. The signif-
icance of expression differences between tested groups was calculated using a two-tailed unpaired
Student’s t-test, for the comparison of two means, by the QuickCalcs on-line software (www.
graphpad.com) and p values<0.05 were considered to be significant. Linear regression analysis
was employed to assess correlation between number of CAG repeats and gene expression levels.
Results
Probing RNA level of PMCA1, SERCA2, SERCA3 and VEGF in
peripheral blood of a limited cohort of HD patients and controls
To address the steady-state level of PMCA1, SERCA2-3 and VEGF transcripts in the peripheral
blood of HD patients and controls, RNA was extracted from PBMCs of 20 HD subjects (10
Table 2. List of genes assessed for their expression level usingmultiplex real-time PCR assays and
annotation.
Gene name/
symbol
Description Applied Biosystems assay
ID
ATP2B1/PMCA1 ATPase, Ca++ transporting, plasma membrane 1 Hs00155949_m1
ATP2A3/SERCA3 ATPase, Ca++ transporting, ubiquitous Hs00193090_m1
ATP2A2/SERCA2 ATPase, Ca++ transporting, cardiac muscle, slow
twitch 2
Hs00544877_m1
VEGF Vascular endothelial growth factor A Hs00900054_m1
doi:10.1371/journal.pone.0125259.t002
Table 3. Primer and probe sequences used for the real-time detection of β-actin.
Name Sequence Length
β -actin 611 (TAMRA probe) ACC ACC ACG GCC GAG CGG 18 bp
β -actin-592F (forward primer) CGA GCG CGG CTA CAG CTT 18 bp
β -actin-651R (reverse primer) TCC TTA ATG TCA CGC ACG ATT T 22 bp
doi:10.1371/journal.pone.0125259.t003
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males, with a mean age of 44.5 ± 10.1, and 10 females, with a mean age of 53.4 ± 9.6) and 20
age-matched (± 3 years) and sex-matched (10 males and 10 females) healthy controls. Each
RNA was reverse transcribed in three independent reactions, and 2 μl of pooled cDNA was
probed for the evaluation of the gene-specific expression level, as described in Materials and
Methods. As shown in Fig 1, the mRNAs of PMCA1 and SERCA3 showed similar levels in the
HD and control groups, both in the male and female subjects. In contrast, the levels of
SERCA2 and VEGF mRNAs were significantly reduced in the HD patients (p<0.005) com-
pared to the age- and sex-matched controls. Because no sex-related differences were found re-
garding the mRNA level of the four genes tested, all further analyses were performed pooling
the results obtained from males and females for both the HD and control subjects.
The mRNA level of SERCA2 is reduced in HDmanifest as well as pre-
manifest subjects and has a negative correlation with the expansion of
the CAG repeat
The steady-state level of SERCA2 mRNA in PBMCs was analysed on a total of 164 subjects
comprised of Italian and Slovenian individuals. In total, 90 HD manifest patients (45 males
and 45 females), 20 pre-manifest carriers of HD causative mutation (10 males and 10 females)
and 54 age- and sex-matched controls (33 males and 22 females) were analysed. Because
SERCA2 gene expression has been reported to be reduced with ageing [57–59], the subjects
analysed were subdivided in three arbitrary age ranges: 27–40, 43–58 and 59–84 years. No pre-
manifest subjects were available in the 59–84 range of age. As shown in Fig 2A, all the HD-af-
fected patients and even all the pre-manifest subjects displayed a highly significant reduction
in SERCA2 mRNA, ranging from p<0.01 and p<0.001, compared with the control mRNA
Fig 1. RNA quantification of PMCA1, SERCA2, SERCA3 and VEGF in PBMCs from healthy controls and HD patients divided according to sex.
Subjects analysed: 10 healthy male controls and 10 healthy female controls age-matched ± 3 years; 10 males HD, mean age of 44.5 ± 10.1; 10 females HD,
mean age of 53.4 ± 9.6. *** p<0.005. Each column represents the relative mean value of three independent experiments ± SD.
doi:10.1371/journal.pone.0125259.g001
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Fig 2. mRNA quantification of the SERCA2 pump relative to the age, clinical conditions and CAG expansion of the patients. (A) Comparison of the
level of SERCA2mRNA in PBMCs from HD pre-manifest and manifest patients and age- and sex-matched healthy controls. Age 27–40: Controls = 15; pre-
manifest = 12; manifest = 13; Age 43–58: Controls = 26; pre-manifest = 8; manifest = 42; Age 59–84: Controls = 13; manifest = 35. ** p<0.01; *** p<0.001.
(B) Comparison of the level of SERCA2 mRNA in PBMCs of patients with different stages of the disease: pre-manifest = 20; early-manifest = 17;
manifest = 55; late-manifest = 18. (C) Correlation between the level of SERCA2 mRNA and the number of CAG repeats (range 37–46) R2 = 0.9611. (D)
Correlation between the level of SERCA2 mRNA and the number of CAG repeats (range 46–56) R2 = 0.6793. The mean values ± SD of three independent
assays are shown.
doi:10.1371/journal.pone.0125259.g002
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levels. However, the reduction of SERCA2 mRNA in the manifest versus pre-manifest subjects
did not reach statistical significance. Furthermore, as shown in Fig 2B, no progressive reduc-
tion of SERCA2 mRNA was observed when stratifying the patients according to their clinical
phenotype, namely, pre-manifest (N = 20), early-manifest (N = 17), manifest (N = 55) and
late-manifest (N = 18). This result suggests that the impairment in SERCA2 gene expression is
not a biomarker of onset and progression of the disease, however it is a precocious sign of
events underlying cellular dysfunction in HD. Interestingly, by plotting the SERCA2 mRNA
level against the number of CAG repeats, in the range of 37 and 46 CAG (Fig 2C), a linear re-
gression of R2 = 0.9611 was observed. No further reduction in SERCA2 RNA was detected for
the 25 HD subjects with CAG expansion greater than 46 repeats, from 47 up to 56 CAG (Fig
2D). In an attempt to ensure cell survival, some compensatory mechanisms may be activated
when a higher CAG expansion is present. Conversely, specific molecular interactions, which
may be responsible for the observed reduction in SERCA2 mRNA, may occur in the case of
lower expansion (37–46 CAG repeats). Further investigation needs to be performed to under-
stand the molecular mechanisms that inversely correlate SERCA2 mRNA expression and CAG
repeats (i.e., 37–46). Some hypotheses on possible mechanisms underlying this observation will
be discussed.
The mRNA level of VEGF is more reduced in HD manifest than in pre-
manifest patients with respect to controls, and no correlation is evident
with the expansion of the CAG repeat
The results obtained by analysing the steady-state levels of VEGF mRNA in the PBMCs of the
same 164 subjects are shown in Fig 3A. As found for SERCA2 mRNA, the VEGF mRNA levels
were also lower in all subjects carrying the mutation, both the pre-manifest (p<0.01) and man-
ifest (p<0.001) subjects, when compared to the sex- and age-matched controls. Moreover, the
mRNA level appeared to be inversely correlated with the onset and progression of the disease.
Indeed, as shown in Fig 3B, by stratifying the patients according to their clinical phenotype, a
significant reduction in VEGF mRNA (p<0.05) was observed in the late-manifest compared to
the early and pre-manifest patients. Although this observation needs to be refined through the
analysis of a greater number of subjects, it suggests a potential role of VEGF as a candidate bio-
marker useful for tracing the progression of Huntington's disease. No correlation was observed
between the level of VEGF mRNA and the number of CAG repeats in any range analysed (data
not shown).
Discussion
The identification of quantitative biomarkers of neurodegeneration that highlights the onset
and/or progression of symptoms remains a priority for patient management and for develop-
ing effective therapies. Huntington’s disease remains an incurable and fatal disease due to a
toxic gain of function by the HTT mutant protein. Recent evidences show that mHTT induces
alterations in areas of the central nervous system as well as in the peripheral tissues of patients
with HD. The availability of peripheral biomarkers for tracing the onset and/or progression of
the disease represents a reasonable goal for the clinical management of HD patients. Within
this context, the number of studies aiming to identify molecular alterations in the peripheral
tissues of patients and/or animal models of HD is increasing. Different attempts to compare
gene expression profiles of HD tissues and matched controls have been made using microarray
technology. Borovecky et al. [18] performed a genome-wide expression profiling of human
blood and showed, in pre-manifest and manifest HD subjects, a significant up-regulation of
genes belonging to many different functional groups, such as transcription / RNA processing,
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ubiquitin / proteasome, vesicle trafficking, and signal transduction, as compared to control
goups. The up-regulation of twelve selected genes has been confirmed through qRT-PCR as-
says. However, these promising results were not reproduced by Runne and co-workers [19] on
a different cohort of HD patients and controls. Nor other potential useful marker has been
found by the peripheral transcriptomic analysis performed by these authors. This suggests that
peripheral transcriptomics fails in providing common validated biomarkers in HD or rather
emphasizes a need for further validations on new and enlarged cohorts of patients.
Fig 3. mRNA quantification of VEGF relative to the age and clinical conditions of the patients. (A) Comparison of the level of VEGFmRNA in PBMCs
from HD pre-manifest, manifest patients and age- and sex-matched healthy controls.Age 27–40: Controls = 15; pre-manifest = 12; manifest = 13; Age 43–58:
Controls = 26; pre-manifest = 8; manifest = 42; Age 59–84: Controls = 13; manifest = 35; ** p<0.01; *** p<0.001. (B) Comparison of the level of VEGF
mRNA in PBMCs of patients with different stages of the disease: pre-manifest = 20; early-manifest = 17; manifest = 55; late-manifest = 18;* p<0.05. The
mean values ± SD of three independent assays are shown.
doi:10.1371/journal.pone.0125259.g003
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Furthermore, differences in array platforms sensitivity and probes design and/or qRT-PCR de-
tection methods and reagents and/or samples preparation methods may account for differ-
ences reported in different studies on gene expression profile in blood. Recently, in the attempt
to find a cell type alternative to blood cells for biomarker studies in HD, Marchina et al. (17)
performed gene expression profiling analysis on skin fibroblasts of HD patients and controls.
Interestingly, in a set of nine genes confirmed to be differentially expressed between HD and
controls the phosphoinositide-specific phospholipase C β4 (PLCβ4) gene is strongly upregu-
lated. PLCβ4 over-expression could be linked to the altered Ca2+ homeostasis in this cell type
in HD. Deregulated Ca2+ homeostasis is a well-established hallmark of HD. Considering the
harmful effects of increased levels of intracellular calcium, the expression and activity of
pumps able to actively counteract the augment of Ca2+ concentration in HD neurons may play
a key role in the onset and/or progression of the disease. Plasma membrane and sarco/endo-
plasmic Ca2+ATPases, namely PMCAs and SERCAs pumps, play a pivotal role in cellular calci-
um homeostasis and in regulating the physiological resting level of calcium [60–61]. In our
study, we adopted a multiplex real-time PCR approach to compare the RNA levels of the
housekeeping-expressed PMCA1 pump and the SERCA2 and SERCA3 pumps in PBMCs iso-
lated from blood samples of patients with HD, pre-manifest subjects and sex- and age-matched
healthy controls. Comparable levels of PMCA1 and SERCA3 mRNAs were found in all HD
and control groups examined, whereas the SERCA2 mRNA level was significantly reduced in
all the subjects carrying the HD causative mutation, both manifest and pre-manifest subjects.
These results suggest that, at least in the cohort of patients we examined, the impairment of
SERCA2 gene expression is an early pathogenetic event underlying peripheral cells dysfunction
in HD. However, because no significant and progressive reduction was observed by comparing
SERCA2 mRNA expression levels in PBMCs from pre-manifest, early-manifest and late-mani-
fest patients, SERCA2 could be considered as a biomarker of the genetic status but not of the
onset or progression of the disease.
It must be said that apparently, the reduction of SERCA2 mRNA level in blood of HD pa-
tient respect to controls is not confirmed by the work of Diamanti et al. (24) on mice models of
HD. Indeed, in the arrays analysis conducted by these authors on peripheral blood of R6/2
mice in the symptomatic stage and wild type littermate mice, even if some of the gene set arrays
contain SERCA2-specific probes no altered expression profile of SERCA2 mRNA has been re-
ported in blood of HD with respect to control mice. A simple explanation of these conflicting
results could be that the microarray assays have a different sensitivity than the QPCR assays.
Alternatively, an intriguing explanation could arise from the observation that the R6/2 mice ex-
press a short fragment of mHTT but carrying a large poly-Q trait (about 110Q). None of the
patients we examined have a similar number of polyQ in the mHTT. Furthermore, as shown in
Fig 2C, we found a significant inverse correlation between the expanded poly-Q tract of mHTT
and the SERCA2 mRNA level only in the range of 37Q-46Q-46QQ. Further expansions of
poly-Q trait (47QQ-56Q) are not accompanied by a further reduction of SERCA2 mRNA level
in blood, rather an opposite finding, though not significant in that group of patients, seems to
exist with more than 46Q (Fig 2D). This observation suggests that peculiar molecular interac-
tion(s) could link the mHTT protein and SERCA2 gene expression in a polyQ-dependent man-
ner. One possible explanation of this could be that different conformational/functional
properties are acquired by the mutant proteins with differently expanded polyQ traits, and this
could affect a gene-specific expression. The first unveiled mechanism drawing transcriptional
alterations in HD was a direct protein-protein interaction of mHTT with transcription factors.
However, a more likely scenario has been depicted by Benn and co-workers [62] in demon-
strating that the wild type and the mutant HTT both bind directly DNA, have different geno-
mic binding sites in vivo, including different gene promoters and sites for transcription factor
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occupancy. The mHTT could inhibit a proper binding of transcription factors to DNA and/or
alter DNA conformation and hence alter the gene transcription. These findings suggest the
need of a more detailed investigation of the gene expression patterns related to a defined ex-
pansion of the poly-Q tract in HD. This is reinforced by our finding showing the occurrence of
a progressive reduction of SERCA2 mRNA level only in a defined range of the poly-Q dimen-
sion. Clarifying the peculiar molecular interaction(s) linking the mutant protein and SERCA2
gene expression could provide new insights in differential and early occurring molecular mech-
anisms that contribute to trigger cellular dysfunction in HD.
Another well-established hallmark of HD is the reduced expression of neurotrophic and
neuroprotective agents. VEGF gene expression has also been found to be impaired in both
manifest and pre-manifest patients, highlighting the need to improve the signalling of neuro-
protective agents in HD. Interestingly, Ellison and co-workers recently exploited a lentiviral-
mediated delivery of VEGF and 82Q mHTT in rat primary striatum cell cultures and in adult
rat striatum, demonstrating a strictly dose-dependent neuroprotection exerted by the VEGF165
isoform in these models of HD [37]. In our study, the level of VEGF mRNA in PBMCs of HD
mutation carriers was found to be inversely correlated with the progression of the disease. In-
deed, when stratifying the patients according to their clinical phenotype, a significant reduction
of VEGF mRNA was observed in blood of late manifest compared to early and pre-manifest
patients. Although this observation needs to be confirmed through the analysis of a larger
number of subjects and on different populations, it suggests a potential role of VEGF mRNA as
a useful candidate biomarker for following up the progression of Huntington's disease.
In conclusion, to the best of our knowledge, data reported here are the only directly address-
ing the Calcium pumps and VEGF mRNA levels in blood of HD. Certainly the work we have
presented has several limitations such as to validate the results obtained on a different cohort
of patients and investigate the possible pathogenetic significance of the reduction of SERCA2
and VEGF mRNAs both in peripheral tissues and the central nervous system of HD patients.
Consistent with the above, the evaluation of SERCA2 and VEGF protein levels in the peripheral
blood of patients and controls is missing. Nevertheless, the data presented are consistent with
the aim of this work that is the search for biomarkers in peripheral blood of HD patients useful
in monitoring the onset and / or progression of the disease. Our overall results suggest that the
evaluation over time of VEGF mRNA level in blood of HD patients could be helpful in moni-
toring the progression of the disease. Moreover, the evaluation of VEGF and SERCA2 mRNAs
both could be helpful in monitoring the response to therapy in clinical trials. Finally, the results
of our study could provide new insight to understand early events that could contribute to cel-
lular dysfunction in HD.
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